학술논문
282TiP - Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study
Document Type
Abstract
Author
Source
In Annals of Oncology October 2018 29 Supplement 8
Subject
Language
ISSN
0923-7534